Back to top

Replimune Group Lawsuit: Company Asks Court to Dismiss Securities Case Over RP1 FDA Approval Process

Replimune Group, Inc. (NASDAQ: REPL) and several current or former company leaders have asked a federal court in Massachusetts to dismiss an invest...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Replimune Group, Inc. (REPL)